FIELD: biochemistry.
SUBSTANCE: invention relates to the field of biochemistry, in particular to a molecule specific to the CD45 and CD79b antigens, where the said molecule contains a binding domain specific to the CD45 antigen and a binding domain specific to the CD79b antigen. The invention also relates to a molecule specific to CD45, CD79b and serum albumin antigens, where the said molecule contains a binding domain specific to CD45 antigen, a binding domain specific to CD79b antigen, and a binding domain specific to serum albumin.
EFFECT: invention is effective in controlling abnormal B-cell functions associated with diseases such as autoimmune diseases and malignancies.
11 cl, 17 dwg, 7 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| LY6G6D ANTIBODIES AND METHODS OF USE | 2020 |
|
RU2818569C1 |
| ANTAGONISTIC ANTIBODIES THAT BIND TO HUMAN TGFβ1, TGFβ2 AND TGFβ3, AND THEIR USE IN TREATMENT OF LUNG FIBROSIS | 2017 |
|
RU2746926C2 |
| MOLECULES WITH SPECIFICITY WITH RESPECT TO CD79 AND CD22 | 2015 |
|
RU2743590C2 |
| ANTIBODIES CONTAINING POLYPEPTIDE INTEGRATED INTO FRAME REGION 3 | 2019 |
|
RU2796254C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
| MULTI-SPECIFIC ANTIBODIES AND METHODS OF THEIR PRODUCTION AND USE | 2018 |
|
RU2811477C2 |
| ANTI-αvβ8 ANTIBODIES AND COMPOSITIONS AND THEIR USE | 2019 |
|
RU2812478C2 |
| COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING INFECTIONS CAUSED BY STAPHYLOCOCCUS AUREUS | 2015 |
|
RU2764981C1 |
| COMBINATION THERAPY BASED ON T-CELL-ACTIVATING BISPECIFIC ANTIGEN-BINDING MOLECULES AGAINST CD3 AND FOLATE RECEPTOR 1 (FOLR1) AND ANTAGONISTS BINDING TO PD-1 AXIS | 2015 |
|
RU2753902C2 |
| AMATOXIN ANTIBODY-DRUG CONJUGATES AND USE THEREOF | 2020 |
|
RU2826004C2 |
